Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Bespoken nanoceria: A new effective treatment in experimental hepatocellular carcinoma.

Fernández-Varo G, Perramón M, Carvajal S, Oró D, Casals E, Boix L, Oller L, Macías-Muñoz L, Marfà S, Casals G, Morales-Ruiz M, Casado P, Cutillas PR, Bruix J, Navasa M, Fuster J, Garcia-Valdecasas JC, Pavel MC, Puntes V, Jiménez W.

Hepatology. 2020 Jan 21. doi: 10.1002/hep.31139. [Epub ahead of print]

PMID:
31961955
2.

Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.

Soto M, Reviejo M, Al-Abdulla R, Romero MR, Macias RIR, Boix L, Bruix J, Serrano MA, Marin JJG.

Biochim Biophys Acta Mol Basis Dis. 2020 Jan 14:165687. doi: 10.1016/j.bbadis.2020.165687. [Epub ahead of print]

PMID:
31953214
3.

Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.

Sanduzzi-Zamparelli M, Sapena V, Bruix J, Reig M.

Aliment Pharmacol Ther. 2020 Jan;51(1):192. doi: 10.1111/apt.15572. No abstract available.

PMID:
31850569
4.

Reply to: "Response to Mariño et al. J Hep 2019 Study: The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".

Sapena V, Rios J, Torres F, Mariño Z, Forns X, Bruix J, Reig M.

J Hepatol. 2019 Dec 13. pii: S0168-8278(19)30715-9. doi: 10.1016/j.jhep.2019.12.003. [Epub ahead of print] No abstract available.

PMID:
31843648
5.

Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues.

Unfried JP, Serrano G, Suárez B, Sangro P, Ferretti V, Prior C, Boix L, Bruix J, Sangro B, Segura V, Fortes P.

Cancer Res. 2019 Oct 15;79(20):5167-5180. doi: 10.1158/0008-5472.CAN-19-0400. Epub 2019 Aug 6.

PMID:
31387921
6.

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Rimola J, Forner A, Sapena V, Llarch N, Darnell A, Díaz A, García-Criado A, Bianchi L, Vilana R, Díaz-González Á, Ayuso C, Bruix J, Reig M.

Eur Radiol. 2020 Jan;30(1):186-194. doi: 10.1007/s00330-019-06351-0. Epub 2019 Aug 1.

PMID:
31372783
7.

Insights into the success and failure of systemic therapy for hepatocellular carcinoma.

Bruix J, da Fonseca LG, Reig M.

Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1. Review.

PMID:
31371809
8.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Nov;19(11):3176-3184. doi: 10.1111/ajt.15551. Epub 2019 Sep 3.

PMID:
31365177
9.

Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".

Sapena V, Rios J, Torres F, Mariño Z, Forns X, Bruix J, Reig M.

J Hepatol. 2019 Aug;71(2):447-448. doi: 10.1016/j.jhep.2019.04.018. Epub 2019 Jun 7. No abstract available.

PMID:
31182374
10.

Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.

Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, Vilana R, Oliveira R, Llarch N, Bruix J.

Liver Int. 2019 Jul;39(7):1281-1291. doi: 10.1111/liv.14133. Epub 2019 May 28.

PMID:
31077539
11.

Medical treatment for cholangiocarcinoma.

Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW.

Liver Int. 2019 May;39 Suppl 1:123-142. doi: 10.1111/liv.14100. Review.

PMID:
30892822
12.

Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty.

Bruix J, Ayuso C.

Gastroenterology. 2019 Mar;156(4):860-862. doi: 10.1053/j.gastro.2019.02.008. Epub 2019 Feb 15. No abstract available.

PMID:
30776351
13.

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.

Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.

Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.

14.

Corrigendum to "Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines" [Eur. J. Radiol. 101 (2018) 72-81].

Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C.

Eur J Radiol. 2019 Mar;112:229. doi: 10.1016/j.ejrad.2019.01.018. Epub 2019 Jan 30. No abstract available.

PMID:
30709654
15.

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.

Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M.

Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29. Review.

PMID:
30695819
16.

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.

Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M.

J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24.

PMID:
30684506
17.

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success.

Da Fonseca LG, Reig M, Bruix J.

Oncotarget. 2018 Sep 18;9(73):33741-33742. doi: 10.18632/oncotarget.26052. eCollection 2018 Sep 18. No abstract available.

18.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.

19.

Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J.

J Hepatol. 2018 Oct;69(4):990-991. doi: 10.1016/j.jhep.2018.07.015. Epub 2018 Aug 10. No abstract available.

PMID:
30104026
20.

Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma.

Díaz-González Á, Monclús E, Darnell A, Solé M, Bruix J.

Hepatology. 2018 Nov;68(5):2042-2044. doi: 10.1002/hep.30120. Epub 2018 Oct 13. No abstract available.

PMID:
30044003
21.

Locoregional versus systemic therapy - robust positive data remain elusive.

Sanduzzi-Zamparelli M, Bruix J.

Nat Rev Clin Oncol. 2018 Sep;15(9):537-538. doi: 10.1038/s41571-018-0047-6. No abstract available.

PMID:
29858583
22.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.

J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

PMID:
29704513
23.

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A.

Oncotarget. 2018 Mar 30;9(24):16701-16717. doi: 10.18632/oncotarget.24673. eCollection 2018 Mar 30.

24.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
25.

Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.

Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C.

Eur J Radiol. 2018 Apr;101:72-81. doi: 10.1016/j.ejrad.2018.01.025. Epub 2018 Jan 31. Review. Erratum in: Eur J Radiol. 2019 Mar;112:229.

PMID:
29571804
26.

Lenvatinib: can a non-inferiority trial change clinical practice?

Reig M, Bruix J.

Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9. No abstract available.

PMID:
29433849
27.

Hepatocellular carcinoma.

Forner A, Reig M, Bruix J.

Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5. Review.

PMID:
29307467
28.

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments.

Reig M, Díaz-González Á, Bruix J.

Oncotarget. 2017 Nov 11;8(63):106151-106152. doi: 10.18632/oncotarget.22382. eCollection 2017 Dec 5. No abstract available.

29.

Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.

Molina V, Sampson-Dávila J, Ferrer J, Fondevila C, Díaz Del Gobbo R, Calatayud D, Bruix J, García-Valdecasas JC, Fuster J.

Surg Endosc. 2018 May;32(5):2345-2354. doi: 10.1007/s00464-017-5930-1. Epub 2017 Dec 7.

PMID:
29218665
30.

Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.

Urtasun N, Boces-Pascual C, Boix L, Bruix J, Pastor-Anglada M, Pérez-Torras S.

Oncotarget. 2017 Oct 6;8(52):90185-90196. doi: 10.18632/oncotarget.21624. eCollection 2017 Oct 27.

31.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

32.

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).

Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC.

Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.

33.

Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".

Bruix J, Lii Cheng A, Llovet J.

J Hepatol. 2018 Mar;68(3):620-621. doi: 10.1016/j.jhep.2017.10.013. Epub 2017 Oct 24. No abstract available.

PMID:
29079287
34.

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M.

Hepatology. 2018 Feb;67(2):612-622. doi: 10.1002/hep.29515. Epub 2018 Jan 2.

35.

Reply.

Sapisochin G, Bruix J.

Hepatology. 2017 Nov;66(5):1704-1705. doi: 10.1002/hep.29412. Epub 2017 Sep 29. No abstract available.

PMID:
28759706
36.

Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication.

Coto-Llerena M, Koutsoudakis G, Boix L, López-Oliva JM, Caro-Pérez N, Fernández-Carrillo C, González P, Gastaminza P, Bruix J, Forns X, Pérez-Del-Pulgar S.

Virus Res. 2017 Aug 15;240:35-46. doi: 10.1016/j.virusres.2017.07.018. Epub 2017 Jul 24.

PMID:
28751105
37.

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J.

J Hepatol. 2017 Nov;67(5):999-1008. doi: 10.1016/j.jhep.2017.06.026. Epub 2017 Jul 4. Erratum in: J Hepatol. 2018 Oct;69(4):990-991.

38.

Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.

Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Cleton A, Ploeger B.

Eur J Pharm Sci. 2017 Nov 15;109S:S149-S153. doi: 10.1016/j.ejps.2017.05.050. Epub 2017 May 23.

39.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.

World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.

40.

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

Reig M, Boix L, Mariño Z, Torres F, Forns X, Bruix J.

Semin Liver Dis. 2017 May;37(2):109-118. doi: 10.1055/s-0037-1601349. Epub 2017 Apr 7. Review.

PMID:
28388736
41.

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Bruix J, Reig M, Sangro B.

J Hepatol. 2017 Jun;66(6):1114-1117. doi: 10.1016/j.jhep.2017.02.032. Epub 2017 Mar 9. No abstract available.

PMID:
28284917
42.

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers.

Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH).

Med Clin (Barc). 2017 Jul 21;149(2):61-71. doi: 10.1016/j.medcli.2016.12.048. Epub 2017 Mar 7. English, Spanish.

PMID:
28279536
43.

Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

Sapisochin G, Bruix J.

Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5. Review.

PMID:
28053342
44.

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma.

Reig M, Boix L, Bruix J.

Liver Int. 2017 Jan;37 Suppl 1:136-139. doi: 10.1111/liv.13321. Review.

PMID:
28052619
45.

Reply.

Sapisochin G, Bruix J.

Hepatology. 2017 May;65(5):1778. doi: 10.1002/hep.28993. Epub 2017 Mar 30. No abstract available.

PMID:
27997680
46.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
47.

Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway.

Boix L, López-Oliva JM, Rhodes AC, Bruix J.

Oncotarget. 2016 Nov 1;7(44):71309-71329. doi: 10.18632/oncotarget.11885.

48.

Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.

Ribeiro de Souza A, Reig M, Bruix J.

Expert Opin Pharmacother. 2016 Oct;17(14):1923-36. doi: 10.1080/14656566.2016.1225722. Review.

PMID:
27598745
49.

Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.

Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J; iCCA International Consortium.

Hepatology. 2016 Oct;64(4):1178-88. doi: 10.1002/hep.28744. Epub 2016 Aug 24.

PMID:
27481548
50.

Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients.

Bruix J.

Hepat Oncol. 2016 Aug;3(3):187-189. doi: 10.2217/hep-2016-0007. Epub 2016 Aug 19.

Supplemental Content

Support Center